JP2018513116A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513116A5 JP2018513116A5 JP2017546603A JP2017546603A JP2018513116A5 JP 2018513116 A5 JP2018513116 A5 JP 2018513116A5 JP 2017546603 A JP2017546603 A JP 2017546603A JP 2017546603 A JP2017546603 A JP 2017546603A JP 2018513116 A5 JP2018513116 A5 JP 2018513116A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr2
- disease
- cdr3
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003810 Interleukin-18 Human genes 0.000 claims description 233
- 108090000171 Interleukin-18 Proteins 0.000 claims description 233
- 102000044166 interleukin-18 binding protein Human genes 0.000 claims description 110
- 108010070145 interleukin-18 binding protein Proteins 0.000 claims description 110
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 67
- 230000027455 binding Effects 0.000 claims description 47
- 201000010099 disease Diseases 0.000 claims description 40
- 239000012634 fragment Substances 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 23
- 210000001124 body fluid Anatomy 0.000 claims description 23
- 239000010839 body fluid Substances 0.000 claims description 23
- 230000037396 body weight Effects 0.000 claims description 22
- 102000001708 Protein Isoforms Human genes 0.000 claims description 18
- 108010029485 Protein Isoforms Proteins 0.000 claims description 18
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 17
- 208000004987 Macrophage activation syndrome Diseases 0.000 claims description 17
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 17
- 201000001270 X-linked lymphoproliferative syndrome 2 Diseases 0.000 claims description 16
- 208000011594 Autoinflammatory disease Diseases 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 12
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 12
- 230000004054 inflammatory process Effects 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims description 10
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 10
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims description 10
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 10
- 230000009885 systemic effect Effects 0.000 claims description 10
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims description 6
- 101000804865 Homo sapiens E3 ubiquitin-protein ligase XIAP Proteins 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 4
- 208000004232 Enteritis Diseases 0.000 claims description 4
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 4
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 4
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 4
- 101000979572 Homo sapiens NLR family CARD domain-containing protein 4 Proteins 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 claims description 4
- 208000008425 Protein deficiency Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 4
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 4
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 230000000366 juvenile effect Effects 0.000 claims description 4
- 238000010606 normalization Methods 0.000 claims description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
- 229960004618 prednisone Drugs 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 206010043207 temporal arteritis Diseases 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 208000006820 Arthralgia Diseases 0.000 claims description 3
- 206010053555 Arthritis bacterial Diseases 0.000 claims description 3
- 208000006311 Pyoderma Diseases 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 239000003435 antirheumatic agent Substances 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 claims description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 claims description 2
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000009766 Blau syndrome Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 2
- 201000004315 EAST syndrome Diseases 0.000 claims description 2
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims description 2
- 208000035874 Excoriation Diseases 0.000 claims description 2
- 102000008857 Ferritin Human genes 0.000 claims description 2
- 108050000784 Ferritin Proteins 0.000 claims description 2
- 238000008416 Ferritin Methods 0.000 claims description 2
- 206010017711 Gangrene Diseases 0.000 claims description 2
- 206010064571 Gene mutation Diseases 0.000 claims description 2
- 101000839032 Giardia intestinalis (strain P15) Flavohemoprotein-2 Proteins 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 206010072010 Hyper IgD syndrome Diseases 0.000 claims description 2
- 208000018208 Hyperimmunoglobulinemia D with periodic fever Diseases 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 2
- 206010023232 Joint swelling Diseases 0.000 claims description 2
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 108700040132 Mevalonate kinases Proteins 0.000 claims description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 238000005299 abrasion Methods 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 201000004982 autoimmune uveitis Diseases 0.000 claims description 2
- 201000003308 autosomal dominant familial periodic fever Diseases 0.000 claims description 2
- 210000001099 axilla Anatomy 0.000 claims description 2
- 208000025255 bacterial arthritis Diseases 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 230000036760 body temperature Effects 0.000 claims description 2
- 210000004087 cornea Anatomy 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 230000007813 immunodeficiency Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 201000004614 iritis Diseases 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 102000002678 mevalonate kinase Human genes 0.000 claims description 2
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 229930192851 perforin Natural products 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000011476 stem cell transplantation Methods 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 102100035017 Interleukin-18-binding protein Human genes 0.000 claims 19
- 101710205006 Interleukin-18-binding protein Proteins 0.000 claims 19
- 150000001413 amino acids Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 description 91
- 239000000203 mixture Substances 0.000 description 65
- 125000003275 alpha amino acid group Chemical group 0.000 description 32
- 239000012530 fluid Substances 0.000 description 8
- 230000009870 specific binding Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 102000004557 Interleukin-18 Receptors Human genes 0.000 description 3
- 108010017537 Interleukin-18 Receptors Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000018528 secretion by tissue Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021112865A JP7818795B2 (ja) | 2015-03-05 | 2021-07-07 | 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15157742 | 2015-03-05 | ||
| EP15157742.6 | 2015-03-05 | ||
| EP15158781 | 2015-03-12 | ||
| EP15158781.3 | 2015-03-12 | ||
| EP15186626.6 | 2015-09-24 | ||
| EP15186626 | 2015-09-24 | ||
| PCT/EP2016/054524 WO2016139297A1 (en) | 2015-03-05 | 2016-03-03 | Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112865A Division JP7818795B2 (ja) | 2015-03-05 | 2021-07-07 | 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513116A JP2018513116A (ja) | 2018-05-24 |
| JP2018513116A5 true JP2018513116A5 (https=) | 2019-04-11 |
| JP7274259B2 JP7274259B2 (ja) | 2023-05-16 |
Family
ID=55453181
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546603A Active JP7274259B2 (ja) | 2015-03-05 | 2016-03-03 | 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体 |
| JP2021112865A Active JP7818795B2 (ja) | 2015-03-05 | 2021-07-07 | 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112865A Active JP7818795B2 (ja) | 2015-03-05 | 2021-07-07 | 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10882905B2 (https=) |
| EP (1) | EP3265807A1 (https=) |
| JP (2) | JP7274259B2 (https=) |
| KR (1) | KR102511343B1 (https=) |
| CN (1) | CN107660150B (https=) |
| AU (1) | AU2016227644B2 (https=) |
| CA (1) | CA2972689A1 (https=) |
| CL (1) | CL2017002237A1 (https=) |
| CO (1) | CO2017008940A2 (https=) |
| IL (1) | IL253292B2 (https=) |
| MX (1) | MX2017010919A (https=) |
| MY (1) | MY194040A (https=) |
| PH (1) | PH12017501402A1 (https=) |
| RU (1) | RU2755691C2 (https=) |
| SG (1) | SG11201706879UA (https=) |
| UA (1) | UA128752C2 (https=) |
| WO (1) | WO2016139297A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115925928A (zh) * | 2013-09-05 | 2023-04-07 | Ab2生物股份有限公司 | 炎性疾病中的il-18结合蛋白(il-18bp) |
| US10882905B2 (en) | 2015-03-05 | 2021-01-05 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases |
| WO2018119425A2 (en) * | 2016-12-22 | 2018-06-28 | Icahn School Of Medicine At Mount Sinai | Anti-lilrb3 antibodies and methods of use thereof |
| CN111315395A (zh) | 2017-09-06 | 2020-06-19 | 耶鲁大学 | 白细胞介素-18变体和使用方法 |
| MA53338A (fr) * | 2018-03-05 | 2022-01-05 | Janssen Pharmaceutica Nv | Dosages pour détecter la neurodégénérescence |
| WO2020018364A1 (en) * | 2018-07-16 | 2020-01-23 | University Of Hawaii | Anti-galectin-9 antibody and methods of use thereof |
| CN108929382B (zh) * | 2018-07-20 | 2019-10-15 | 深圳市第三人民医院 | 一种抗serinc5的抗体及其应用 |
| US12269874B2 (en) | 2018-12-03 | 2025-04-08 | mAbProtein Co., Ltd. | Antibody that recognizes neoepitope of activated interleukin-18 proteins and application thereof |
| JP7631203B2 (ja) | 2019-01-18 | 2025-02-18 | ユニバーシティ ヘルス ネットワーク | Ｌｉｌｒｂ３結合分子とその使用 |
| US12594330B2 (en) | 2019-06-04 | 2026-04-07 | Regents Of The University Of Minnesota | Anti-opioid compounds and methods of making and using same |
| CN112582058B (zh) * | 2019-11-07 | 2022-04-01 | 广州医科大学 | 一种基于空气质量的慢阻肺发病预测方法及系统 |
| US20230173021A1 (en) | 2020-05-06 | 2023-06-08 | Ab2 Bio Sa | IL-18 Binding Protein (IL-18BP) In Respiratory Diseases |
| GB202007404D0 (en) | 2020-05-19 | 2020-07-01 | Nasser Syed Muhammad Tahir | Treatment for viral respiratory infections |
| TW202210511A (zh) * | 2020-06-01 | 2022-03-16 | 美商阿法羅醫療股份有限公司 | 涉及il-18抗體之方法及治療 |
| EP3943097A1 (en) | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t cell therapy |
| JP2023549257A (ja) | 2020-11-18 | 2023-11-22 | ノバルティス アーゲー | Ｎｌｒｃ４－ｇｏｆインフラマソーム病の処置における使用のための二特異性抗体 |
| WO2023067348A1 (en) | 2021-10-21 | 2023-04-27 | Biosirius Ltd | Treatment for virally-induced pneumonia |
| MX2024007616A (es) * | 2021-12-20 | 2024-09-04 | Avalo Therapeutics Inc | Métodos y tratamiento para la enfermedad de still de inicio en la edad adulta y la artritis idiopática juvenil de inicio sistemico que implica anticuerpos contra il-18. |
| CN120737196A (zh) * | 2022-01-28 | 2025-10-03 | 和径医药科技（上海）有限公司 | 一种靶向il-18bp的抗体及其应用 |
| CA3244428A1 (en) | 2022-03-04 | 2023-09-07 | Ab2 Bio Sa | IL-18 BINDING PROTEIN (IL-18BP) IN THE TREATMENT OF VEXAS SYNDROME |
| PE20251671A1 (es) * | 2022-03-15 | 2025-06-30 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer |
| IL321948A (en) | 2023-01-06 | 2025-09-01 | Lassen Therapeutics Inc | Anti-IL-18 BP antibodies |
| EP4646270A2 (en) | 2023-01-06 | 2025-11-12 | Alector LLC | Anti-il18 binding protein antibodies and methods of use thereof |
| WO2026038145A1 (en) | 2024-08-13 | 2026-02-19 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) and methods of using same |
| CN119192356B (zh) * | 2024-09-29 | 2025-05-27 | 华中农业大学 | 识别犬瘟热病毒h蛋白的单克隆抗体、检测试纸条及应用 |
| CN119241693B (zh) * | 2024-09-29 | 2025-05-27 | 华中农业大学 | 一种抗犬瘟热病毒的基因工程嵌合抗体及应用 |
| CN120349409B (zh) * | 2025-04-08 | 2026-03-17 | 生物岛实验室 | Il-18bp纳米抗体及其制备方法与应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| ATE190629T1 (de) | 1991-01-18 | 2000-04-15 | Amgen Inc | Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| WO1996013590A2 (en) | 1994-10-21 | 1996-05-09 | Innogenetics N.V. | New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
| CA2340579A1 (en) * | 1998-09-01 | 2000-03-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin 18-binding protein |
| AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
| TWI335336B (https=) | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
| NZ520122A (en) * | 2000-02-21 | 2005-04-29 | Applied Research Systems | Use of IL-18 inhibitors |
| TR200502061T2 (tr) * | 2000-02-21 | 2005-08-22 | Research Systems Ars Holding N. V. Applied | IL-18 inhibitörlerinin kullanımı. |
| EE05056B1 (et) | 2000-05-05 | 2008-08-15 | Applied Research Systems Ars Holding N.V. | IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette nhtud ateroskleroosi ravimiseks ja/v?i ennetamiseks |
| US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| EA013564B1 (ru) | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
| AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| HU229164B1 (en) | 2001-01-29 | 2013-09-30 | Serono Sa Coinsins Lab | Use of il-18 inhibitors for the treatment and/or prevention of heart disease |
| ES2334773T3 (es) | 2001-05-16 | 2010-03-16 | Yeda Research And Development Co. Ltd. | Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis. |
| PL216228B1 (pl) * | 2001-05-25 | 2014-03-31 | Ares Trading Sa | Zastosowanie białka wiążącego IL-18 |
| SI1487541T1 (sl) * | 2002-03-22 | 2009-02-28 | Serono Lab | Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja |
| MXPA05003869A (es) * | 2002-10-08 | 2005-06-22 | Ares Trading Sa | El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina. |
| GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| DK1601776T3 (da) | 2003-03-11 | 2008-10-13 | Serono Lab | Ekspressionsvektorer omfattende mCmV-IE2-promotoren |
| US20080076708A1 (en) | 2003-05-13 | 2008-03-27 | Valter Altarocca | Active Variants of the Il-18 Binding Protein and Medical Uses Thereof |
| AU2011224023C1 (en) | 2003-11-12 | 2013-08-29 | Abbvie Inc. | IL-18 binding proteins |
| US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| IL159670A0 (en) * | 2003-12-31 | 2004-06-01 | Yeda Res & Dev | Use of il-18 binding protein in inflammations |
| WO2005087249A1 (ja) | 2004-03-11 | 2005-09-22 | Kurume University | プロテアーゼ阻害剤及び疾患の予防又は治療剤 |
| CA2572921C (en) | 2004-07-09 | 2017-01-03 | The University Of North Carolina At Chapel Hill | Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants |
| EP1793859B1 (en) | 2004-08-20 | 2009-03-25 | Smithkline Beecham Corporation | Treatment of oral and intestinal mucositis by administering human il-18 |
| EP2267024B1 (en) | 2005-06-03 | 2012-05-09 | Ares Trading S.A. | Production of recombinant Il-18 binding protein |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| DE602006021038D1 (de) | 2005-09-15 | 2011-05-12 | Univ Mcgill | Verfahren zur diagnose eines ovarialkarzinoms |
| WO2008091592A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
| KR20140003467A (ko) * | 2010-12-20 | 2014-01-09 | 메디뮨 리미티드 | 항il-18 항체 및 그의 용도 |
| US9376489B2 (en) | 2012-09-07 | 2016-06-28 | Novartis Ag | IL-18 binding molecules |
| CN115925928A (zh) * | 2013-09-05 | 2023-04-07 | Ab2生物股份有限公司 | 炎性疾病中的il-18结合蛋白(il-18bp) |
| US10882905B2 (en) * | 2015-03-05 | 2021-01-05 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases |
-
2016
- 2016-03-03 US US15/555,446 patent/US10882905B2/en active Active
- 2016-03-03 KR KR1020177024957A patent/KR102511343B1/ko active Active
- 2016-03-03 RU RU2017134857A patent/RU2755691C2/ru active
- 2016-03-03 CA CA2972689A patent/CA2972689A1/en active Pending
- 2016-03-03 JP JP2017546603A patent/JP7274259B2/ja active Active
- 2016-03-03 SG SG11201706879UA patent/SG11201706879UA/en unknown
- 2016-03-03 UA UAA201709701A patent/UA128752C2/uk unknown
- 2016-03-03 CN CN201680013699.2A patent/CN107660150B/zh active Active
- 2016-03-03 MY MYPI2017001041A patent/MY194040A/en unknown
- 2016-03-03 WO PCT/EP2016/054524 patent/WO2016139297A1/en not_active Ceased
- 2016-03-03 AU AU2016227644A patent/AU2016227644B2/en active Active
- 2016-03-03 MX MX2017010919A patent/MX2017010919A/es unknown
- 2016-03-03 EP EP16707773.4A patent/EP3265807A1/en active Pending
-
2017
- 2017-07-03 IL IL253292A patent/IL253292B2/en unknown
- 2017-08-04 PH PH12017501402A patent/PH12017501402A1/en unknown
- 2017-08-31 CO CONC2017/0008940A patent/CO2017008940A2/es unknown
- 2017-09-04 CL CL2017002237A patent/CL2017002237A1/es unknown
-
2020
- 2020-05-26 US US16/883,906 patent/US11820817B2/en active Active
-
2021
- 2021-03-08 US US17/195,518 patent/US11926663B2/en active Active
- 2021-07-07 JP JP2021112865A patent/JP7818795B2/ja active Active
-
2024
- 2024-02-08 US US18/436,802 patent/US20240190952A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513116A5 (https=) | ||
| RU2017134857A (ru) | Il-18-связывающие белок (il-18bp) и антитела при воспалительных заболеваниях | |
| US20230250164A1 (en) | IL-18 Binding Protein (IL-18BP) In Inflammatory Diseases | |
| JP2016536332A5 (https=) | ||
| JP2010534478A (ja) | Ｉｌ−１８受容体抗原結合タンパク質 | |
| WO2015120185A1 (en) | Novel assay to detect human periostin | |
| BR112016030568B1 (pt) | Método ex vivo para determinar se uma dose compreendendo uma proteína semelhante a anticorpo de região v dupla ou seu fragmento administrada a um indivíduo humano se liga especificamente a il-4 ou il-13 no indivíduo humano | |
| JP2019525928A (ja) | 抗体及び抗ウイルス剤の抗ｈｓｖ相乗作用 | |
| CN119968391A (zh) | 用抗白细胞介素-33抗体治疗哮喘 | |
| TH1701005048A (th) | โปรตีนเข้าจับ il-18 (il-18bp) และ แอนติบอดีในโรคที่มีการอักเสบ | |
| TW202210511A (zh) | 涉及il-18抗體之方法及治療 | |
| US20230091430A1 (en) | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION | |
| TWI865759B (zh) | 涉及過量游離light之方法及治療 | |
| EP4301408A1 (en) | Treatment of atopic dermatitis employing anti-il-13ralpha1 antibody or binding fragment thereof in an allergic population | |
| WO2025186779A1 (en) | Oncolytic viruses expressing immunomodulators and use for treating advanced solid tumor | |
| CN114641494A (zh) | 抗-33治疗剂fpr治疗肾脏障碍 | |
| HK40123339A (zh) | 针对april的抗体分子及其用途 | |
| NZ733897B2 (en) | Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases | |
| HK1221726B (en) | Il-18 binding protein (il-18bp) in inflammatory diseases |